You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

  1. PLASMA & BIOTHERAPIES - 20-06-2019

    First patient enrolled and treated in Kedrion’s CARES10 clinical study

    Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

    read more 

  2. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 

  3. PLASMA & BIOTHERAPIES - 08-11-2016

    FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin

    Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017

    read more 

  4. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 

Pages

For more information please contact: pressoffice@kedrion.com